Evaluate the Safety and Efficacy of a Biofield Energy Treated Proprietary Dietary Supplement (TRI 360™) on Psychological Symptoms, Mental Disorders, Emotional Well-being, and Quality of Life in Adult Subjects.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

The demand for "energy healing" is growing rapidly in the United States and other developed countries.

Who Took Part

According to the abstract, 77 subjects were involved.

The age groups tagged for this paper are adults, both men and women.

A total of 77 adult subjects (male and female) aged 20-45 years with one or more psychological symptoms were enrolled in the trial.

The subjects were randomized into two groups: placebo control and treatment group.

How the Study Was Run

The researchers set it up as a randomized, double-blind, open-label and placebo-controlled study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.

Being open-label, the Copper (Supplement) study did not mask who received what.

A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.

The placebo control group (n = 42) did not receive any treatment/capsule.

An open-label, single-center, randomized controlled trial (RCT).

Adult human subjects (male and female) with one or more psychological symptoms.

Biofield energy treated proprietary capsule.

What Was Measured

Topics PubMed links to this paper include Cytokines, Biomarkers, Dietary Supplements, Mental Disorders and Quality of Life.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Copper (Supplement) in 77 subjects.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Alternative therapies in health and medicine), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.